Sebia Diagnostics India Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 2.16 Cr
as on 15-11-2024
- Company Age 5 Year, 24 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
as on 15-11-2024
- Revenue 27.76%
(FY 2023)
- Profit 1433.23%
(FY 2023)
- Ebitda 80197.28%
(FY 2023)
- Net Worth 32.87%
(FY 2023)
- Total Assets 43.00%
(FY 2023)
About Sebia Diagnostics India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.16 Cr.
The company currently has active open charges totaling ₹1.00 Cr.
Rahul Aggarwal, Guru Acharya, Vincent Verfaillie, and One other member serve as directors at the Company.
- CIN/LLPIN
U85110HR2019FTC083840
- Company No.
083840
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
26 Nov 2019
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sebia Diagnostics India?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Aggarwal  | Director | Current | |
| Guru Acharya | Director | 05-Feb-2024 | Current |
Vincent Verfaillie  | Director | Current | |
| Kamal Sharma | Director | 26-Nov-2019 | Current |
Financial Performance and Corporate Structure Insights of Sebia Diagnostics India.
Sebia Diagnostics India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 27.76% increase. The company also saw a substantial improvement in profitability, with a 1433.23% increase in profit. The company's net worth Soared by an impressive increase of 32.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sebia Diagnostics India?
In 2023, Sebia Diagnostics India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 18 Aug 2021 | ₹1.00 Cr | Open |
How Many Employees Work at Sebia Diagnostics India?
Sebia Diagnostics India has a workforce of 30 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sebia Diagnostics India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sebia Diagnostics India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
